BORTEGA

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 3.5 mg bortezomib (as mannitol boronic ester).

After reconstitution, 1 ml of bortezomib subcutaneous solution for injection contains 2.5 mg.
After reconstitution, 1 ml of bortezomib intravenous solution contains 1 mg.

THERAPEUTIC INDICATIONS

Bortega as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

Bortega in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.

Other indications find in SPC.

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.